Novartis adds another Cosentyx approval with FDA nod
This article was originally published in Scrip
The FDA on 21 January gave its blessing to Novartis to market Cosentyx (secukinumab) as a treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
You may also be interested in...
Next up for Cosentyx is psoriatic arthritis and ankylosing spondylitis. Novartis presented impressive long-term efficacy data at ACR in PsA and AS. Incoming CEO and Chief Medical Officer Vas Narasimhan said the company sees a blockbuster opportunity and is exploring the anti-TNF naïve market in AS.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.